|Market Cap (Intraday)||655.88M|
|2yr Forward PE||N/A|
Immatics N.V Stock, NASDAQ:IMTX
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.